LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
LIPELLA PHARMACEUTICALS INC.
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $2.27K
- P/E (TTM)
- –
- Dividend yield
- –
Lipella Pharmaceuticals statistics
Financials through Sep 30, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.31K | $164.85M |
| Enterprise Value | -$1.85M | $87.06M |
| PS Ratio | 0.01 | 3.60 |
| PB Ratio | 0.00 | 2.03 |
| P/TBV Ratio | 0.00 | 2.31 |
Enterprise value
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | -4.76 | 2.43 |
Income (trailing twelve months)
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $389.78K | $57.94M |
| Operating Income | -$5.41M | -$21.44M |
| Pretax Income | -$5.33M | -$14.45M |
| Net Income | -$5.33M | -$22.46M |
| EBITDA | -$5.41M | -$16.91M |
| EPS (Diluted) | -$2.42 | -$0.83 |
Margins
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -1387.9% | -44.5% |
| Pretax Margin | -1367.4% | -13.0% |
| Profit Margin | -1367.4% | -39.2% |
| EBITDA Margin | -1387.2% | -31.3% |
Returns
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -361.8% | -53.1% |
| Return on Assets (ROA) | -236.4% | -41.0% |
| Return on Capital Employed (ROCE) | -316.9% | -37.8% |
Growth
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -19.4% | 6.01% |
| Revenue Growth (3Y CAGR) | 27.4% | 2.25% |
Balance sheet
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.86M | $62.42M |
| Net Cash (Debt) | $1.86M | $15.68M |
| Net Cash Per Share | $0.40 | $0.66 |
| Equity (Book Value) | $1.49M | $48.79M |
| Book Value Per Share | $0.32 | $1.36 |
| Tangible Book Value | $1.49M | $23.06M |
| Working Capital | $1.44M | $75.77M |
Financial position
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.24 | 3.30 |
| Quick Ratio | 2.89 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$4.78M | -$12.35M |
Efficiency
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.17 | 0.38 |
| Revenue Per Employee | $77.96K | $398.96K |
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 5 | 74 |
Dividends and yields
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -230684.0% | -22.7% |
Shares
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 4,620,840 | 58,179,650 |
| Shares Change (YoY) | 216.7% | 11.1% |
| Shares Change (QoQ) | 3.43% | 0.54% |
| Float | 3,512,350 | 49,173,100 |
| Shares Held by Insiders | 24.0% | 11.6% |
Scores
| Measure | Lipella Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -18.15 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Lipella Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.